Company profile
Ampio Pharmaceuticals, Inc.
OTC: AMPE · Healthcare · Biotechnology
#863 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 12GM —SS 37
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ disclosure history, return on equity
Methodology →Revenue TTM
$245.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.6M
Employees
6
as of 2026-08-27
Market cap
$207.9k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.2M$1.2M2015
Net income-$8.6M-$8.6M2023
Operating income-$33.3M-$33.3M2015
Total assets$5.7M$5.7M2023
Liabilities$2.4M$2.4M2023
Equity$3.4M$3.4M2023
Revenue trend
FY2015 – FY2015 · USD
FY15
FY15
FY15
FY15
FY15
FY15
FY15
FY15
Revenue by segment
Filed disclosures · FY2015
By product
Aytu100%
By geography
Not disclosed.
The read
What is Ampio Pharmaceuticals, Inc.’s revenue?
Ampio Pharmaceuticals, Inc. booked $1.2M in FY2015 revenue, growing 139% year over year — faster than most Healthcare companies we track, at a -742.6% net margin.
Peers · Healthcare
Longeveron Inc.30DSOHM, Inc.61CPeoplesway.com Inc.——PetVivo Holdings, Inc.38DRenovoRx, Inc.32DBespoke Extracts, Inc.——Neighbors
Arapahoe →Key facts
CEOMichael A. Martino
SectorHealthcare
IndustryBiotechnology
HeadquartersEnglewood, CO
ExchangeOTC: AMPE
Employees6
IPO date2010-03-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.